Ginkgo Bioworks Holdings Management
Management criteria checks 3/4
Ginkgo Bioworks Holdings' CEO is Jason Kelly, appointed in Jan 2008, has a tenure of 16.83 years. total yearly compensation is $262.50K, comprised of 95.2% salary and 4.8% bonuses, including company stock and options. directly owns 3.84% of the company’s shares, worth $15.63M. The average tenure of the management team and the board of directors is 6.3 years and 2.7 years respectively.
Key information
Jason Kelly
Chief executive officer
US$262.5k
Total compensation
| CEO salary percentage | 95.2% |
| CEO tenure | 16.8yrs |
| CEO ownership | 3.8% |
| Management average tenure | 6.3yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Ginkgo Bioworks: Not Enough Progress
Nov 13Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%
Oct 04Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$651m |
| Jun 30 2024 | n/a | n/a | -US$898m |
| Mar 31 2024 | n/a | n/a | -US$854m |
| Dec 31 2023 | US$263k | US$250k | -US$893m |
| Sep 30 2023 | n/a | n/a | -US$857m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$263k | US$250k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$4b |
| Jun 30 2022 | n/a | n/a | -US$3b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$381m | US$250k | -US$2b |
| Sep 30 2021 | n/a | n/a | -US$276m |
| Jun 30 2021 | n/a | n/a | -US$200m |
| Mar 31 2021 | n/a | n/a | -US$175m |
| Dec 31 2020 | US$11m | US$250k | -US$127m |
Compensation vs Market: Jason's total compensation ($USD262.50K) is below average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
CEO
Jason Kelly (43 yo)
16.8yrs
Tenure
US$262,500
Compensation
Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.8yrs | US$262.50k | 3.84% $ 15.6m | |
| Founder | 16.8yrs | US$262.50k | 4.18% $ 17.0m | |
| Chief Financial Officer | 4yrs | US$1.69m | 0.084% $ 343.8k | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | 4.28% $ 17.4m | |
| Founder | no data | no data | 4.17% $ 17.0m | |
| Chief Accounting Officer | 1.5yrs | no data | 0.012% $ 47.2k | |
| General Counsel & Secretary | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Head of People | 6.8yrs | no data | no data | |
| Head of Design | 6.1yrs | no data | no data | |
| Head of Omics & Analytical Chemistry | 6.3yrs | no data | no data |
6.3yrs
Average Tenure
43yo
Average Age
Experienced Management: DNA's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 16.8yrs | US$262.50k | 3.84% $ 15.6m | |
| Founder | 16.8yrs | US$262.50k | 4.18% $ 17.0m | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 3.2yrs | US$459.38k | 0.037% $ 150.6k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Independent Director | 8.8yrs | US$477.50k | 0.060% $ 244.8k | |
| Independent Director | 2.3yrs | US$448.67k | 0.0075% $ 30.5k | |
| Independent Director | 3.2yrs | US$457.50k | 0.031% $ 127.0k | |
| Independent Chairman of the Board | 9.8yrs | US$485.19k | 0.11% $ 450.0k | |
| Member of Biopharma Advisory Board | less than a year | no data | no data | |
| Member of Biopharma Advisory Board | less than a year | no data | no data |
2.7yrs
Average Tenure
62yo
Average Age
Experienced Board: DNA's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.